Sarah Elitzur
A5087639742- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Immunodeficiency and Autoimmune Disorders
- MicroRNA in disease regulation
- Lymphoma Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Hemoglobinopathies and Related Disorders
- Virus-based gene therapy research
- DNA Repair Mechanisms
- Viral-associated cancers and disorders
- Pharmaceutical studies and practices
- Blood disorders and treatments
- Genomics and Rare Diseases
- Epigenetics and DNA Methylation
- Hematopoietic Stem Cell Transplantation
- Autoimmune and Inflammatory Disorders Research
Schneider Children's Medical Center
2016-2025
Tel Aviv University
2016-2025
Azienda Ospedaliera San Gerardo
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Medizinische Hochschule Hannover
2022
Sheba Medical Center
2005
PURPOSE Off-label use of vemurafenib (VMF) to treat BRAF V600E mutation–positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses Disease Activity Score. RESULTS...
A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood
Relapsed precursor T-cell acute lymphoblastic leukemia is characterized by resistance against chemotherapy and frequently fatal. We aimed at understanding the molecular mechanisms resulting in relapse of analyzed 13 patients first diagnosis, remission whole exome sequencing, targeted ultra-deep multiplex ligation dependent probe amplification DNA methylation array. Compared to primary leukemia, number single nucleotide variants small insertions deletions approximately doubled from 11.5 26....
PURPOSE We determined the prognostic factors and utility of allogeneic hematopoietic cell transplantation among children with newly diagnosed hypodiploid acute lymphoblastic leukemia (ALL) treated in contemporary clinical trials. PATIENTS AND METHODS This retrospective study collected data on 306 patients ALL who were enrolled protocols 16 cooperative groups or institutions between 1997 2013. The biologic characteristics, early therapeutic responses as by minimal residual disease (MRD)...
Genetic abnormalities provide vital diagnostic and prognostic information in pediatric acute lymphoblastic leukemia (ALL) are increasingly used to assign patients risk groups. We recently proposed a novel classifier based on the copy-number alteration (CNA) profile of 8 most commonly deleted genes B-cell precursor ALL. This defined 3 CNA subgroups consecutive UK trials was able discriminate with intermediate-risk cytogenetics. In this study, we sought validate United Kingdom ALL (UKALL)-CNA...
We aimed to study prognostic factors and efficacy of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in first remission patients with noninfant childhood acute lymphoblastic leukemia (ALL) 11q23/
ABL-class fusions other than BCR-ABL1 characterize around 2-3% of precursor B-cell acute lymphoblastic leukemia. Case series indicated that patients suffering from these subtypes have a dismal outcome and may benefit the introduction tyrosine kinase inhibitors. We analyzed clinical characteristics 46 fusion positive cases treated according to AIEOP-BFM (Associazione Italiana di Ematologia-Oncologia Pediatrica-Berlin-Frankfurt-Münster) ALL 2000 2009 protocols; 13 them received inhibitor (TKI)...
Abstract In children with acute lymphoblastic leukemia (ALL), risk groups for invasive fungal disease (IFD) need antifungal prophylaxis are not well characterized, and the advent of new compounds, current data on outcome scarce. Prospectively captured serious adverse event reports enrolled in international, multi-center clinical trial AIEOP-BFM ALL2009 were screened proven/probable IFD, defined according to updated EORTC/MSG consensus definitions. a total 6136 (median age 5.2 years), 224...
Abstract A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study 1256 children with KMT2A-r AML aims to validate prognostic value established recurring KMT2A fusions and additional aberrations (ACAs) define additional, ACAs, evaluating their relevance. Compared our previous study, 3 groups were...
Abstract Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand and genetic features of this found age drivers were significantly associated outcome. diagnosed in under 3 years was extremely high-risk enriched for alterations that result both LMO2 activation STAG2 inactivation. Mechanistically, using patient samples isogenic cell lines, we show...
Not available.
Abstract Viral infections pose a significant global burden. Host susceptibility to pathogens is determined by many factors including genetic variation that can lead immunodeficient or dysregulated antiviral immune responses. Pax5 heterozygosity ( −/+ ), resulting in reduced PAX5 levels mice, mimics germline somatic dysregulation contributing diseases such as childhood B-cell precursor acute lymphoblastic leukemia (B-ALL). In contrast the well-characterized roles of during early development,...
Our aim was to identify miRNAs that can predict risk of relapse in pediatric patients with acute lymphoblastic leukemia (ALL). Following high‐throughput miRNA expression analysis (48 samples), five miRs were selected for further confirmation performed by real time quantitative PCR on a cohort precursor B‐cell ALL ( n = 138). The results correlated clinical parameters and outcome. Low miR‐151‐5p, miR‐451, high miR‐1290 or combination all three predicted inferior free survival P 0.007, 0.042,...
COVID-19, the novel coronavirus has caused a global pandemic affecting millions of people around world. Although children, including children with cancer, have been found to be affected less commonly and severely than adults, indirect effects on diagnosis treatment cancer described. A survey was performed in four largest tertiary pediatric hematology-oncology medical centers Israel. Clinical laboratory data were collected from files patients diagnosed or treated during April–October 2020....
Current evidence indicates sub-optimal incidence of fertility preservation (FP) in eligible patients. We present herein our designated multidisciplinary program for FP pediatric and adolescent population data on female Pediatric patients (age 0–18) who were candidate highly gonadotoxic treatments referred to a discussion gonadal risk-assessment followed by either oocyte cryopreservation or ovarian (OCP) patients, sperm banking male The OCP protocol consists aspiration oocytes from small...
Abstract Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at cost significant life‐threatening toxicity. The bispecific T‐cell engager blinatumomab, recently approved for relapsed/refractory ALL, a unique nonmyelotoxic toxicity profile. As blinatumomab causes B‐cell depletion, safety its use during severe chemotherapy‐induced is unclear. We report 11 patients with...